Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02723006 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
A Phase 1 study, sponsored by Millennium Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02723006 is a Phase 1 study that was terminated before completion, run by Millennium Pharmaceuticals. The registered enrollment target is 22 participants.
The verdict
NCT02723006, a Phase 1 study, was terminated before completion, sponsored by Millennium Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors \[nivolumab, ipilimumab\] with investigational drugs \[TAK-580, TAK-202 (plozalizumab), vedolizumab\]) in the 3 arms when administered to participants with advanced melanoma.
Interventions
- DRUG nivolumab
- DRUG ipilimumab
- DRUG vedolizumab
- DRUG TAK-580
- DRUG TAK-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2016-06-22 |
| Est. Completion | 2018-05-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02723006
The ClinicalTrials.gov registry entry for NCT02723006 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which nivolumab is the first listed.
NCT02723006 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02723006 about?
NCT02723006 is a clinical study titled "Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma". The purpose of this study is to determine the initial safety profile and initial antitumor activity of the combination treatments (immune checkpoint inhibitors \[nivolumab, ipilimumab\] with investigational drugs \[TAK-580, TAK-202 (plozalizumab), vedolizumab\]) in the 3 arms when administered to pa...
What is the current status of trial NCT02723006?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2016-06-22. Estimated completion is 2018-05-11.
What interventions are being tested in trial NCT02723006?
The interventions under investigation include: nivolumab (DRUG), ipilimumab (DRUG), vedolizumab (DRUG), TAK-580 (DRUG), TAK-202 (DRUG).
Who is sponsoring clinical trial NCT02723006?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.